Últimas noticias sobre Traws Pharma (NASDAQ:TRAW) Bolsa

Traws Pharma

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.

Konskie,,Poland,-,March,08,,2025:,Restoration,Hardware,Company,Logo

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADBE

BIAF

CGBS

EONR

FGEN

GNLN

HCTI

HUSA

INDO

NINE

PRZO

RNTX

RSLS

SBET

TPET

TRAW

USEG

VEON

RH sorprende con ganancias positivas en el primer trimestre y mantiene su guía para 2025, mientras sus acciones suben un 18,2 %.

Las acciones de RH se disparan un 18%; Aquí están 20 acciones que se mueven antes de la apertura del mercado

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

Traws Pharma Inc

TraWell Co SpA

A mother who depends on <a href="https://www.benzinga.com/personal-finance/management/25/06/46073802/she-thought-her-ssi-ended-at-18-now-shes-worried-her-mom-may-still-be-collecting-it">Supplemental Security Income</a> is now facing a long suspension of her benefits — all because of a car accident settlement that didn't turn out the way anyone expected.
According to a post shared in the <a href="https://www.reddit.com/r/SocialSecurity/comments/1m60bqw/moms_ssi_suspended_she_won_a_settlement_of_25000/">r/SocialSecurity forum</a> on Reddit, the woman was awarded $25,000 from a 2021 car accident. But after years of delays, legal fees, and Medicaid reimbursement, she only received a little over $8,000 — and not until early this year.
Despite that, the post says the Social Security Administration is treating it like she had the full $25,000 in her bank account since 2021. That misunderstanding has now left her without her monthly SSI benefits — and trying to figure out what to do next.
Don't Miss:
<ul class="wp-block-list">
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">SSI Has a Hard Cap on What You Can Own</h2>
SSI is designed to help people with low income and limited resources, but those resources are tightly monitored. In order to stay eligible, <a href="https://www.ssa.gov/ssi/spotlights/spot-transfer-resources.htm">SSA rules</a> say you can't have more than $2,000 in countable assets if you're single — or $3,000 for couples.
Countable resources include things like cash, bank account balances, stocks, property (other than your primary home) and most other items that can be sold or converted to money. One-time payments, like a settlement or inheritance, count toward that limit.
Even if you only have the money temporarily, going over the resource cap — even for just one day — can make you ineligible for that month's SSI payment.
<h2 class="wp-block-heading">Why Giving the Money Away Isn't the Solution</h2>
The Reddit user asked whether giving the remaining $8,000 to family members or grandchildren would help her mom qualify for SSI again.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a>
Unfortunately, it doesn't work that way. Giving away money while on SSI is considered a "transfer of resources," and the SSA can penalize you by suspending benefits for up to 36 months. That's because transferring assets for less than their full value — including gifts — is seen as an attempt to bypass the resource limit.
One Reddit commenter put it bluntly: "Who in their right mind gives away $8,000 when they&#8217;re poor? Don&#8217;t you think SSA will be asking this same [question]?"
<h2 class="wp-block-heading">The Right Way to Spend Down the Money</h2>
There is a path forward — but it requires careful documentation. To get back on SSI, the woman needs to show that she spent the $8,000 on allowable expenses and didn't just hand it off or stash it.
Some suggestions from commenters included:
<ul class="wp-block-list">
<li>Buying a new car or repairing an old one</li>
<li>Paying for a full year of car insurance</li>
<li>Making necessary home repairs</li>
<li>Purchasing household items, groceries, or medical supplies</li>
<li>Replacing furniture or essential appliances</li>
</ul>
The key is to spend the money in a traceable way — ideally through a bank account, with receipts — so the SSA can clearly see where the money went.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">If You're in a Similar Situation</h2>
Getting a settlement, back pay, or other lump sum while on SSI can be tricky. Here are a few tips to stay on the right side of the rules:
<ul class="wp-block-list">
<li>Report the money to SSA immediately</li>
<li>Don't withdraw it all in cash — use a bank account to create a paper trail</li>
<li>Spend down the funds carefully, only on necessary items</li>
<li>Keep receipts and records of everything</li>
<li>Don't gift the money to others — it could result in a longer suspension</li>
</ul>
Even a relatively small windfall can lead to serious consequences if handled the wrong way. For those relying on SSI, it's essential to understand how one-time payments can affect eligibility — and to plan carefully to <a href="https://www.benzinga.com/personal-finance/management/25/07/46206467/social-security-says-she-owes-4765-but-could-the-monthly-rule-save-her-from-paying-back-money-she-didnt-earn">protect your benefits</a>.
Read Next: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Image: Shutterstock

Personal Finance

How A $25K Car Crash Settlement Could Leave This Mom Without SSI For Years

DRMAW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

DRMA

Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 10.16% on an annualized basis producing an average annual return of 21.8%. Currently, Apollo Asset Management has a market capitalization of $83.05 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 10 years ago, it would be worth $7,074.98 today based on a price of $145.32 for APO at the time of writing.
<h3>Apollo Asset Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754004614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Barrington Research analyst Kevin Steinke maintains Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) with a Outperform and maintains $10 price target.

Price Target

Analyst Ratings

QUAD

Barrington Research Maintains Outperform on Quad/Graphics, Maintains $10 Price Target

Barrington Research analyst Alexander Paris maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Outperform and raises the price target from $200 to $240.

Barrington Research Maintains Outperform on Affiliated Managers Group, Raises Price Target to $240

Macquarie analyst Paul Golding maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Outperform and raises the price target from $380 to $425.

Macquarie Maintains Outperform on Visa, Raises Price Target to $425

TD Securities analyst Cherilyn Radbourne maintains Canadian Pacific Kansas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CP#TSX">CP</a>) with a Hold and raises the price target from C$117 to C$118.

TSX:CP

TD Securities Maintains Hold on Canadian Pacific Kansas, Raises Price Target to C$118

TD Securities analyst Aaron Macneil maintains Precision Drilling (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PD#TSX">PD</a>) with a Hold and raises the price target from C$71 to C$77.

TSX:PD

TD Securities Maintains Hold on Precision Drilling, Raises Price Target to C$77

UBS analyst Amit Mehrotra maintains Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Buy and raises the price target from $135 to $173.

UBS Maintains Buy on Vertiv Holdings, Raises Price Target to $173

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) has outperformed the market over the past 5 years by 12.98% on an annualized basis producing an average annual return of 26.85%. Currently, Pure Storage has a market capitalization of $19.45 billion. 
Buying $1000 In PSTG: If an investor had bought $1000 of PSTG stock 5 years ago, it would be worth $3,290.22 today based on a price of $59.51 for PSTG at the time of writing.
<h3>Pure Storage's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754003713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PSTG

Here's How Much $1000 Invested In Pure Storage 5 Years Ago Would Be Worth Today

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Overweight and raises the price target from $741 to $756.

ARGX

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $756

Citigroup analyst Joanne Wuensch maintains GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) with a Buy and raises the price target from $89 to $93.

GEHC

Citigroup Maintains Buy on GE HealthCare Techs, Raises Price Target to $93

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and raises the price target from $415 to $490.

CVNA

Citigroup Maintains Buy on Carvana, Raises Price Target to $490

Citigroup analyst Ariel Rosa maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $127 to $114.

Citigroup Maintains Buy on United Parcel Service, Lowers Price Target to $114

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) with a Buy and raises the price target from $45 to $49.

LENZ

Citigroup Maintains Buy on LENZ Therapeutics, Raises Price Target to $49

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $78 to $88.

Citigroup Maintains Buy on Western Digital, Raises Price Target to $88

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $803 to $915.

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $915

BlackRock is going deeper into the hard hat area of the <a href="https://www.benzinga.com/etfs">ETF market.</a> The giant asset manager debuted its first-ever actively managed infrastructure ETF, the iShares Infrastructure Active ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILT#NYSE">BILT</a>), on Thursday, a move that highlights the increasing popularity of infrastructure as a long-term growth vehicle.
For many decades, infrastructure investing was the investment equivalent of eating your vegetables, not thrilling but good for you. But with increasing global energy transitions, AI-hungry infrastructure that demands data and reconfigured supply chains, investors are now looking at infrastructure with fresh enthusiasm. BlackRock&#8217;s new ETF seeks to provide investors with diversified and agile exposure to this high-potential space.
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46766110/4-unlikely-etfs-hit-52-week-highs-the-markets-just-catching-on-to-what-they-know">4 Unlikely ETFs Hit 52-Week Highs — The Market&#8217;s Just Catching On To What They Know</a>
<h2 class="wp-block-heading">How BILT&#8217;s Engine Is Built</h2>
The ETF includes 50 to 60 listed global infrastructure names, ranging from transport terminals to energy storage, utilities and building legends. Instead of passively following broad indexes, BILT employs an active strategy. The expense ratio of the ETF is 0.60%, and it tracks the FTSE Developed Core Infrastructure 50/50 Net TR Index.
The launch occurs as global infrastructure spending is expected to reach $68 trillion by 2040, driven by megatrends such as digitalization, energy independence, and supply chain reorganisation.
BILT complements BlackRock&#8217;s current $10 billion infrastructure ETF line-up consisting of:
<ul class="wp-block-list">
<li>iShares Global Infrastructure ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGF#NASDAQ">IGF</a>)</li>
<li>iShares U.S. Infrastructure ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IFRA#BATS">IFRA</a>)</li>
<li>iShares U.S. Digital Infrastructure and Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDGT#NYSE">IDGT</a>)</li>
</ul>
Simultaneously, BlackRock&#8217;s larger infrastructure business, Global Infrastructure Partners, oversees approximately $183 billion across 300-plus investments in more than 100 nations.
While infrastructure businesses tend to go unnoticed within global indexes, Morrison said that it&#8217;s precisely this under-allocation that makes BILT so strong. The ETF offers access to an asset class that has historically been less volatile than global equities, but without giving up growth opportunity.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46763938/from-seoul-to-wall-street-how-trumps-south-korea-tariff-truce-could-reshape-etf-strategies">From Seoul To Wall Street: How Trump&#8217;s South Korea Tariff Truce Could Reshape ETF Strategies</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

BILT

iShares U.S. Digital Infrastructure and Real Estate ETF

IDGT

IFRA

iShares S&P Global Infrastructure Index Fund

BlackRock's New ETF BILT Bets On $68 Trillion Boom, But Most Investors Are Missing It

Health Care

Press Releases

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates  Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma Announces Management Updates

Earnings

Traws Pharma Reports Full Year 2024 Results and Business Highlights

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!

Comments

Traws Pharma

Noticias

Últimas noticias sobre Traws Pharma (NASDAQ:TRAW) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL